Science - "Opening Industry-Academic Partnerships"

 – April 12, 2013  –– 

Collaborations between industry and academia are promoted by open innovation programs, which have become a near-universal model for R&D. Pharmaceutical and biotechnology companies offer university researchers access to resources and funding. Academic scientists bring in-depth expertise and basic research data to the table. Dr. Stuart A. Aaronson, professor of oncological sciences, Icahn School of Medicine at Mount Sinai, and Gadi Bornstein, Pfizer associate research fellow, are collaborators at the New York-based CTI. Their project is developing therapeutic antibodies against an oncogenic target. "It's been a good experience," says Dr. Aaronson. "We feel like we're moving together to a common goal, and we've had consensus so far on what's important to pursue." Learn more